fbpx

molecules of the month

Icenticaftor

mutant + WT CFTR Cl channel potentiator

oral 300 mg BID , Ph. II in COPD and CF

from 1M cmpd cell-based HTS + opt.

J. Med. Chem., May 24, 2021

Millenium/Takeda, Cambridge, MA

Icenticaftor
2 mins read

The Novartis mutant and WT CFTR potentiator, icenticaftor (QBW251), is an oral Ph. II clinical candidate for chronic obstructive pulmonary disease (COPD), which is anticipated to become the 3rd leading cause of death globally. The compound had positive proof of concept studies in both cystic fibrosis and COPD, and the advancement of a WT CFTR modulator into the large COPD indication is a significant development. Since there are not good PK/PD models for cystic fibrosis, the candidate was nominated based on in vitro properties and safety studies, but has shown target engagement in humans via biomarkers such as sweat chloride. This is a great medicinal chemistry case study as the starting point for icenticaftor was objectively unattractive, with furan, aniline, and ester…


request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.


already a member? log in: